1. Home
  2. NAT vs AKBA Comparison

NAT vs AKBA Comparison

Compare NAT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nordic American Tankers Limited

NAT

Nordic American Tankers Limited

HOLD

Current Price

$3.91

Market Cap

825.8M

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.52

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAT
AKBA
Founded
1995
2007
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
825.8M
729.1M
IPO Year
1997
2014

Fundamental Metrics

Financial Performance
Metric
NAT
AKBA
Price
$3.91
$1.52
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$3.25
$6.25
AVG Volume (30 Days)
2.9M
2.7M
Earning Date
02-27-2026
11-10-2025
Dividend Yield
8.70%
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$294,820,000.00
$225,071,000.00
Revenue This Year
N/A
$52.38
Revenue Next Year
$25.84
$22.45
P/E Ratio
$434.39
N/A
Revenue Growth
N/A
32.49
52 Week Low
$2.13
$1.45
52 Week High
$3.93
$4.08

Technical Indicators

Market Signals
Indicator
NAT
AKBA
Relative Strength Index (RSI) 70.83 39.71
Support Level $3.36 $1.46
Resistance Level $3.51 $1.57
Average True Range (ATR) 0.11 0.06
MACD 0.06 0.00
Stochastic Oscillator 96.69 20.37

Price Performance

Historical Comparison
NAT
AKBA

About NAT Nordic American Tankers Limited

Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: